WDR5 Inhibitors Targeting MLL1 Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Mixed Lineage Leukemia (MLL) are hindered by the complexity of chromosomal rearrangements and the lack of effective inhibitors targeting the MLL1-WDR5 interaction, which is critical for HMT activity and leukemic transformation.
Innovation Solution
Development of 6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-2-yl-containing compounds that inhibit the binding of MLL1 to WDR5, disrupting the MLL1-WDR5 protein-protein interaction to block MLL1 methyltransferase activity and induce cell-cycle arrest and apoptosis in leukemia cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for MLL leukemia are used, then treatment is provided, but the complexity of chromosomal rearrangements and lack of effective inhibitors limits therapeutic effectiveness
Solution Approach 1:
The patent extracts and targets the critical MLL1-WDR5 protein-protein interaction interface, developing inhibitors that specifically bind to WDR5 to prevent MLL1 association. This approach isolates the essential interaction required for HMT activity and leukemic transformation, providing a focused therapeutic strategy despite the complex background of chromosomal rearrangements
Solution Approach 2:
The WDR5 inhibitors developed in this patent have broad applicability across different MLL leukemia subtypes and potentially other cancer types with WDR5 involvement. The compounds target a conserved interaction interface that is essential for MLL1 function regardless of the specific chromosomal rearrangement, providing a universal therapeutic approach
2Reliability
If MLL1-WDR5 interaction is inhibited, then HMT activity and leukemic transformation are blocked, but the complexity of achieving specific inhibition without affecting other WDR5 interactions arises
Solution Approach 1:
The patent employs peptidomimetic compounds designed to specifically mimic the MLL1 WIN motif sequence and structure, enabling selective binding to the MLL1-WDR5 interaction interface. The local structural features of the WIN motif are replicated in the inhibitors, providing specificity for this particular protein-protein interaction while allowing potential differentiation from other WDR5 binding partners
3Reliability
If peptidomimetic inhibitors are developed, then MLL1 methyltransferase activity is blocked, but the challenge of achieving sufficient potency and selectivity remains
Solution Approach 1:
The patent systematically varies key parameters of the peptidomimetic structure including the core scaffold, side chain substitutions, and molecular flexibility to optimize binding affinity and selectivity. By changing these structural parameters, the researchers have developed compounds with improved potency and selectivity profiles for inhibiting the MLL1-WDR5 interaction
Data Source
AI summary
Described are compounds that disrupt the WDR5-MLL1 protein-protein interaction, pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating disorders and conditions in a subject.